Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STING1 | Q86WV6 | 10/20 | 0.51 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.50 |
| ▸ | HINT1 | P49773 | 3/20 | 0.49 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116029 | 0.85 | TAAR1 (0.53) | STING1PDE3BPDE3ATAAR1HINT1 | |
| SCHEMBL2402056 | 0.83 | AHCY (0.54) | — | |
| SCHEMBL20149811 | 0.82 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL25504648 | 0.82 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL22983981 | 0.82 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL14946363 | 0.82 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL20149810 | 0.82 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL9964274 | 0.82 | STING1 (0.60) | STING1PDE3BPDE3A | |
| SCHEMBL20154883 | 0.75 | HINT1 (0.46) | STING1PDE3BPDE3ATAAR1HINT1 | |
| SCHEMBL22968528 | 0.75 | HINT1 (0.46) | STING1PDE3BPDE3ATAAR1HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026349-B2 | Polynucleotide synthesis labeling chemistry | DHARMACON, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | DHARMACON, INC. | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009612-A1 | Novel Polynucleotide Synthesis Labeling Chemistry | POLN, POLRMT, POLM | STING1 1788/4885PDE3B 2467/4885PDE3A 1803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.